Apricus Biosciences Will Request Approval of Vitaros(R) as a Treatment for Erectile Dysfunction in Switzerland, Based on Guidance From Swiss Regulatory Authorities
SAN DIEGO, May 19, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) announced today that it will file a marketing application in Switzerland for Vitaros® as a treatment for patients with erectile dysfunction ("ED"), based on a positive response it has received from Swissmedic, the Swiss Agency for Therapeutic Products.